The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.
The company's Irys genome mapping technology provides researchers with a non-sequencing-based tool that is essential for studying structural variation.
BioNano plans to develop structural variant assays on its Irys system for diagnostic use in China as a first step in bringing its technology to the clinic.
The assays will incorporate BioNano's Irys next-generation mapping platform, which is designed to image, map, and analyze DNA at the single-molecule level.
The hybrid approach expands on one described last year by Mount Sinai researchers, and relies on short-read sequencing, linked-read sequencing, and genome mapping.
